Do Traders Think Black Diamond Therapeutics Inc (BDTX) Can Turn Around Tuesday?

Black Diamond Therapeutics Inc (BDTX) stock is lower by 13.92% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Black Diamond Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BDTX!

See Full BDTX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With BDTX Stock Today?

Black Diamond Therapeutics Inc (BDTX) stock is trading at $2.35 as of 1:21 PM on Tuesday, Oct 17, a rise of $0.21, or 9.81% from the previous closing price of $2.14. The stock has traded between $2.08 and $2.37 so far today. Volume today is more active than usual. So far 983,782 shares have traded compared to average volume of 538,610 shares.

More About Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. Click Here to get the full Stock Report for Black Diamond Therapeutics Inc stock.